Sabin’s Ciro de Quadros Represents New Canaan Institute in Spain
NEW CANAAN, CT, November 4, 2003—The Sabin Vaccine Institute, a non-profit research and education organization based in New Canaan, today concluded the second meeting of the Cancer Vaccine Consortium (CVC). The three-day meeting was held in Bethesda, Maryland and drew attendees from the United States, Canada and Europe. The purpose of the CVC is to enhance collaboration among companies undertaking research and development on cancer immunotherapies.
Meeting In Bethesda, Maryland Focuses On Regulatory and Intellectual Property Issues
NEW CANAAN, CT, October 27, 2003—The Sabin Vaccine Institute announced the appointment of Nathan Tinker, PhD, as executive director of the Cancer Vaccine Consortium (CVC), a new initiative of the decade- old New Canaan-based non-profit organization. Dr. Tinker, a resident of Norwalk, will be the principal organizer of the Consortium program, which works with a growing list of biopharmaceutical companies to advance discovery of new therapies for a range of cancers. Dr.
Administrator of Key Programmatic Area Draws from Business Leadership Expertise
NEW CANAAN, CT—Robert H. Abplanalp, a major sponsor of the Albert B. Sabin Vaccine Institute, died August 30 at his home in Bronxville, NY. He was 81 years old and had cancer.
Businessman, Inventor Was President Nixon’s Friend
NEW CANAAN, CT—Treatment options for a variety of cancers are expanding to include an array of exciting new approaches. Along with well-established companies, newer biotechnology and biopharmaceutical firms are looking to break into an emerging market that would provide vaccines for both solid cancers—such as melanoma, prostate, breast, lung, cervical, colon, brain, and ovarian—and blood borne cancers—such as lymphoma, leukemia, and myeloma.
Cancer Vaccine Consortium Promotes Collaboration to Introduce New Therapeutic Vaccines
WASHINGTON, D.C.— Two recent studies released by the WASHINGTON, D.C.— Two recent studies released by the American Journal of Preventive Medicine and the